Real‐World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey

Background: The management of relapsed/refractory multiple myeloma (RRMM) remains complex due to early exposure to multiple drug classes since the first treatment line. Aims: To evaluate treatment patterns and identify unmet clinical needs in RRMM across Italian hematology centers. Methods: A national survey was conducted among hematologists experienced in MM care and working in 71 centers, collecting aggregated data on treatment lines, regimens, and clinician perceptions. Results: Upfront daratumumab-based regimens were used most frequently. Lenalidomide and anti-CD38 refractoriness emerged early, limiting options in 2L/3L. Anti-BCMA therapies were broadly endorsed. Conclusions: Despite therapeutic advances for MM, real-world data reveal significant treatment variability and reinforce the need for shared guidelines and innovative therapies. : The authors have confirmed clinical trial registration is not needed for this submission.

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2026-07-25
DOI
https://doi.org/10.1002/jha2.70354
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real‐World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey

Paola Fazi, Alfonso Piciocchi, Valeria Sargentini, Messina Messina et al.
eJHaem
Multiple Myeloma Research and Treatments
article

Real‐World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey

Paola Fazi, Alfonso Piciocchi, Valeria Sargentini, Messina Messina, Paolo de Fabritiis, Sara Bringhen, Francesca Fazio, E Zamagni, P Musto, Stefano Soddu, F Di Raimondo, Massimo Gentile, Michele Cavo, MariaTeresa Petrucci, Francesca Patriarca, Giuseppe Mele, Maurizio Offidani
article en

Abstract

Background: The management of relapsed/refractory multiple myeloma (RRMM) remains complex due to early exposure to multiple drug classes since the first treatment line. Aims: To evaluate treatment patterns and identify unmet clinical needs in RRMM across Italian hematology centers. Methods: A national survey was conducted among hematologists experienced in MM care and working in 71 centers, collecting aggregated data on treatment lines, regimens, and clinician perceptions. Results: Upfront daratumumab-based regimens were used most frequently. Lenalidomide and anti-CD38 refractoriness emerged early, limiting options in 2L/3L. Anti-BCMA therapies were broadly endorsed. Conclusions: Despite therapeutic advances for MM, real-world data reveal significant treatment variability and reinforce the need for shared guidelines and innovative therapies. : The authors have confirmed clinical trial registration is not needed for this submission.

eJHaemVol. 7(4)
Marche Polytechnic University (IT), University of Udine (IT), Policlinico Umberto I (IT), University of Catania (IT), Ospedali Riuniti di Ancona (IT), Fondazione Gimema Onlus (IT), Ospedale Santa Maria della Misericordia di Udine (IT), Policlinico Universitario di Catania (IT), Ospedale Annunziata di Cosenza (IT), Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT), Gruppo Italiano per il Trapianto di Midollo Osseo (IT), University of Calabria (IT), University of Bari Aldo Moro (IT), University of Bologna (IT)
Openalex Percentile: Top 9%
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.